Several other compounds that attenuate NAFLD and lipid metabolism in the liver through the AMPK/SIRT1/PGC1α pathway have been described [338,339,340,341]. This evidence concerns the gene PRKAA2 and metabolic dysfunction-associated steatotic liver disease.